Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 4/20 | 0.44 |
| ▸ | GABRD | O14764 | 4/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.44 |
| ▸ | GABRE | P78334 | 4/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18131976 | 0.88 | JAK2 (0.46) | DYRK1AJAK2GABRPGABRDGABRA1 | |
| SCHEMBL3607833 | 0.87 | JAK2 (0.59) | DYRK1AJAK2BTK | |
| SCHEMBL3612956 | 0.83 | NR4A2 (0.51) | JAK2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL10476463 | 0.83 | JAK2 (0.45) | DYRK1AJAK2GABRPGABRDGABRA1 | |
| SCHEMBL20164978 | 0.81 | GPR17 (0.43) | JAK2KMT2A | |
| SCHEMBL18132018 | 0.81 | JAK2 (0.56) | JAK2KDM4E | |
| SCHEMBL11733230 | 0.79 | PBRM1 (0.59) | DYRK1APBRM1GABRPGABRDGABRA1 | |
| SCHEMBL5821750 | 0.77 | MEN1 (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13503482 | 0.77 | GABRA1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18132109 | 0.77 | GABRA1 (0.44) | DYRK1AGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280418-B1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| EP-3280418-A1 | AZACARBAZOLE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016161570-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164284-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164284-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | BTK, SYK, LYN | DYRK1A 101/4885PBRM1 2356/4885JAK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.